Myristoleic acid
CAS No. 544-64-9
Myristoleic acid( (Z)-Tetradec-9-enoic acid | cis-9-tetradecenoic acid | 9-Tetradecenoic acid )
Catalog No. M28356 CAS No. 544-64-9
Myristoleic acid is a cytotoxic component in the extract from Serenoa repens. Myristoleic acid induces apoptosis and necrosis in human prostatic LNCaP cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 34 | In Stock |
|
| 25MG | 55 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMyristoleic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionMyristoleic acid is a cytotoxic component in the extract from Serenoa repens. Myristoleic acid induces apoptosis and necrosis in human prostatic LNCaP cells.
-
DescriptionMyristoleic acid is a cytotoxic component in the extract from Serenoa repens. Myristoleic acid induces apoptosis and necrosis in human prostatic LNCaP cells.(In Vitro):Myristoleic acid induces both necrosis (100 μg/mL, 81.8%) and apoptosis (100 μg/mL, 89.5%) in LNCaP cells . Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation. (In Vivo):Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice .
-
In VitroMyristoleic acid induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells. Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation. Cell Proliferation Assay Cell Line:Human prostatic carcinoma LNCaP cells.Concentration:0, 50, 100, 150, 200, 250 μg/mL.Incubation Time:24 h.Result:When LNCaP cells were treated with 130 μg/mL extract or 100 μg/mL myristoleic acid for 24 hr, the proportion of apoptotic cells was 16.5 and 8.8%, and that of necrotic one was 46.8 and 81.8%, respectively.
-
In VivoMyristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice. Animal Model:C57BL/6 mice at 5 weeks. Dosage:0.2, 2 mg/kg Administration:IP every 24 h for 4 days.Result:Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner.
-
Synonyms(Z)-Tetradec-9-enoic acid | cis-9-tetradecenoic acid | 9-Tetradecenoic acid
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorSARS-CoV-2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number544-64-9
-
Formula Weight226.36
-
Molecular FormulaC14H26O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (441.77 mM)
-
SMILESCCCC\C=C/CCCCCCCC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Han SH, et al. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro). J Med Chem. 2022 Feb 24;65(4):2880-2904.
molnova catalog
related products
-
Valinomycin
Valinomycin is a cyclic depsipeptide antibiotic and a potassium-specific ionophore.Valinomycin induces PINK1 activation and promotes Parkin phosphorylation at Ser65.
-
1-beta-D-Arabinofura...
1-beta-D-Arabinofuranosylthymine (Thymine 1-β-D-arabinofuranoside) is a purine nucleoside analog. Purine nucleoside analogs have a broad spectrum of antitumor activity, targeting inert lymphoid malignancies and inducing apoptosis.
-
Gomisin N
Gomisin N isolated from Schisandra chinensis produces beneficial sedative and hypnotic bioactivity. It has the potential for use in the treatment of allergy and inhibits proliferation and induces apoptosis in cancer.
Cart
sales@molnova.com